Guerbet’s Elucirem Injection Is Released for Use in Contrast-Enhanced MRI

February 6, 2023—Guerbet recently announced the first production batch of Elucirem (gadopiclenol) injection has been manufactured and released. In September 2022, the company announced FDA approval of Elucirem for contrast-enhanced MRI.

According to the company, Elucirem is a next-generation, highly stable, macrocyclic gadolinium-based contrast agent (GBCA) with high relaxivity for MRI. It is indicated for use in adults and children aged ≥ 2 years.

Elucirem injection is used to detect and visualize lesions with abnormal vascularity in the central nervous system (brain, spine, and associated tissues) and the body (head and neck, thorax, abdomen, pelvis, and musculoskeletal system).

In the press release, Guerbet explained that GBCAs improve the contrast between lesions and surrounding tissues by accelerating the relaxation of protons because of interaction with gadolinium atoms. Gadopiclenol, the active drug substance of Elucirem, has been designed to enable twice as much interaction, resulting in the highest relaxivity among all nonspecific GBCAs. This allows for use at half the conventional gadolinium dose to reveal high-quality images, noted the company.

Elucirem, now available for order, is manufactured by Liebel-Flarsheim Company LLC, a Guerbet Group company based in Raleigh, North Carolina.